Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $53
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the price target from $50 to $53.
Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the price target from $50 to $53.